HOLON, ISRAEL, May 6, 2024
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a
clinical-stage cancer immunotherapy company and a pioneer in
computational target discovery, today announced that the
Company will release its first quarter 2024 financial results on
Monday, May 20, 2024, before the U.S.
financial markets open. Management will host a conference call and
webcast to review the results and provide a corporate update at
8:30 AM ET.
To access the live conference call by telephone, please dial
1-866-744-5399 from the U.S.,or +972-3-918-0644 internationally.
The call will be available via live webcast through Compugen's
website, located at the following link. Following the live webcast,
a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and
development company utilizing its broadly applicable predictive
computational discovery capabilities to identify new drug targets
and biological pathways for developing cancer
immunotherapies. Compugen has developed two proprietary
product candidates: COM701, a potential first-in-class anti-PVRIG
antibody and COM902, a potential best-in-class antibody
targeting TIGIT for the treatment of solid tumors. Compugen also
has a clinical stage partnered program, rilvegostomig (previously
AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT
component is derived from Compugen's clinical stage anti-TIGIT
antibody, COM902, in Phase 3 development by AstraZeneca through a
license agreement for the development of bispecific and
multispecific antibodies. In addition, the Company's
therapeutic pipeline of early-stage immuno-oncology programs
consists of programs aiming to address various mechanisms of immune
resistance, of which the most advanced program, COM503, is in IND
enabling studies is licensed to Gilead. COM503 is a potential
first-in-class, high affinity antibody which blocks the interaction
between IL-18 binding protein and IL-18, thereby freeing natural
IL-18 in the tumor microenvironment to inhibit cancer growth.
Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are
listed on Nasdaq and the Tel Aviv Stock Exchange under the
ticker symbol CGEN
Company contact:
Yvonne
Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original
content:https://www.prnewswire.com/news-releases/compugen-to-release-first-quarter-2024-results-on-monday-may-20-2024-302136627.html
SOURCE Compugen Ltd.